The phospho-ERα (Tyr-537) antibody is a specialized tool used to detect estrogen receptor alpha (ERα) when phosphorylated at tyrosine residue 537. a post-translational modification critical for ERα activity. ERα, a nuclear hormone receptor, mediates estrogen signaling in target tissues, regulating gene expression involved in cell proliferation, differentiation, and survival. Phosphorylation at Tyr-537. located in the receptor’s ligand-binding domain, is associated with ligand-independent activation, influencing receptor dimerization, coactivator recruitment, and transcriptional activity. This modification may occur via Src family kinases or other tyrosine kinases, contributing to ERα’s role in hormone-responsive cancers, particularly breast cancer.
The antibody is widely used in research to study ERα activation dynamics, especially in contexts of endocrine resistance or aberrant signaling in malignancies. By detecting phosphorylated ERα, it helps elucidate mechanisms underlying tumor progression, metastasis, and therapeutic response. Validation typically includes Western blotting, immunohistochemistry, or immunofluorescence in cell lines or tissue samples with known ERα phosphorylation status. Researchers also use it to explore cross-talk between growth factor signaling pathways (e.g., EGFR/HER2) and ERα, which may drive resistance to anti-estrogen therapies. Understanding Tyr-537 phosphorylation provides insights into ERα’s non-genomic signaling and its potential as a biomarker or therapeutic target in oncology.